PO.ET02.14 · 实验与分子治疗
Tumor Microenvironment, Multispecifics, and Immunomodulation
-
-
-
-
- 5836 5836 Augmented antitumor activity of Tumor Treating Fields (TTFields) with anti-VEGFR and docetaxel treatment in a lung cancer mouse model Helena Mumblat, Yara Eid Mutlak, Yuval Shmueli, Ruslana Militsin, Catherine Tempel-Brami, Shay Cahal, Alexandra Volodin, Sara Jacobovitch, Martin Gabay, Itai Tzchori, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
-
-
-
- 5840 5840 The development of minocycline-loaded microparticles and injectable alginate scaffolds composites to prolong release for the treatment of glioblastoma Florestella Rivera, Dorina A. Madrid, Samantha C. Davila, Serenade Trevino, Jorge L. De Leon, Sebastian Flores, Sue Anne Chew
-
- 5842 5842 Combined KRAS pathway inhibition and liposomal irinotecan treatment enhances tumor regression, attenuates desmoplasia, and augments T cell infiltration in pancreatic ductal adenocarcinoma Hari Krishnareddy Rachamala, Fang Wei, Debabrata Mukhopadhyay, Hani M. Babiker
- 5843 5843 Beyond viability: Post treatment single cell and spatial transcriptomic profiling in mixtures of PRISM barcoded cancer cell lines Laura Doherty, Ashish B. George, Mustafa Kocak, Paul Lund, Andrew Kohlway, Andrew Boddicker, Ben Song, Carlos Ruiz Perez, Bryan Lajoie, Catarina D. Campbell, Matthew G. Rees, Jennifer A. Roth
- 5844 5844 Novel inhibition of transcriptional cyclin-dependent kinases, CDK12/13, using CT7439 as a treatment for colorectal cancer with CDK12 upregulation Jason A. Somarelli, Wylie Katherine Watlington, Divya Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu
-
- 5846 5846 AVA6103 is a FAP-enabled pre|CISION ® peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Francis Wilson, Michelle Morrow
- 5848 5848 Targeting phosphodiesterase 10A by ADT-030 normalizes the tumor immune microenvironment by inhibiting RAS-MAPK signaling in both cancer cells and myeloid-derived suppressor cells Gazi Md Yeashin, Ogacheko David Okoko, Yan Ye, Xin Wang, Khalda Fadlalla, Adam Keeton, Yulia Maxuitenko, Xi Chen, Lynn Hedrick, Huidong Shi, Gary A. Piazza, Gang Zhou
-
-
- 5851 5851 (Common-light-chain-antibody+nano-body) × multi-matrix-immunization platform facilitates the development of antitumor multispecific antibody drugs Yi Gu, Xinde Liu, Peng Li, Feng He, Feng Hao, JInying Ning
- 5852 5852 A novel CD33 and TRAIL-R2 targeting bispecific antibody to treat relapsed/refractory acute myeloid leukemia Shiva Bhowmik, William Brady, Kaitlyn Ko, Sheng Cai, William Grossman, Naval Daver, Jonathan Gerber, Herbert Kim Lyerly
- 5853 5853 Bispecific and biparatopic antibodies targeting tumor-specific Tn-glycoepitopes on MUC1 and MUC4 enable broad, selective tumor coverage in epithelial cancers Nisha Shrestha, Boris Klebanov, Aaron C. Groen, Constantine Theodoropulos, Hans H. Wandall
- 5855 5855 NECTIN4×PD-L1 bispecific antibody-drug conjugate integrating checkpoint blockade and targeted cytotoxicity for urothelial carcinoma and lung squamous cell carcinoma Kyoung-Ho Pyo, Seong-Hyun Park, Dongsop Lee, Haneol Kim, Younggyu Kong, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Hyeonseok Jin, Aera Lee, Hojeong Hong, Ju Hwan Kim, Hyungseok Choi, Mi-Kyung Kim, Taedong Han
- 5856 5856 Hanjugator camptothecin platform: Effective, low-toxicity design maximizing antibody functionality and delivering potential best-in-class EGFR/cMet bispecific antibody-drug conjugate Rui Liu, Ge Song, Yushi Chi, Lingli Zhang, Fan Yang, Junjie Zhang, Boqi Gu, Chencheng Han, Xiayan Zhang, Wan-jen Yang, Xiaomu Cheng, Xiaoling Yuan, Yi Zhang, Zhiliang Lv, Qian Zou, Huixin Yan, Chen Hu, Jijun Yuan
- 5857 5857 LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate for the treatment of CDH17-positive gastrointestinal cancer Yang Ye, Yurong Qin, Xingxing Fang, Xiaoya Liu, Tingting Li, Chengze Ni, Peng Zhang, Chao Chu, Mi Ye, Huan Lin, Wanting Wang, Guojin Wu, Jianming Sun, Hui Yuwen, Yuanzhi Lv, Jing Guan, Min Chen, Yue Zhao, Jordan Zhu, Charles Cai, Xiao Huang, Xiaoqiang Kang, Hong Ling
-
-
